Agios Pharm

Company Profile

Agios Pharm had its IPO on 2013-07-24 under the ticker symbol AGIO.

The company operates in the Healthcare sector and Biotechnology industry. Agios Pharm has a staff strength of 389 employees.

Stock update

Shares of Agios Pharm opened at $23.26 at the start of the last trading session i.e. 2023-03-30.

The stocks traded within a range of $22.53 - $23.57, and closed at $22.55.

This is a -2.51% slip from the previous day's closing price.

A total volume of 569,305 shares were traded at the close of the day’s session.

In the last one week, shares of Agios Pharm have increased by +3.49%.

Agios Pharm's Key Ratios

Agios Pharm has a market cap of $1.30 billion, indicating a price to book ratio of 1.623 and a price to sales ratio of 164.392.

In the last 12-months Agios Pharm’s revenue was $14.24 million with a gross profit of $12.54 million and an EBITDA of $-380483008. The EBITDA ratio measures Agios Pharm's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Agios Pharm’s operating margin was -2732.07% while its return on assets stood at -18.17% with a return of equity of -19.38%.

In Q4, Agios Pharm’s quarterly earnings growth was a positive 0% while revenue growth was a positive 24.3%.

Agios Pharm’s PE and PEG Ratio

Forward PE

2.4655

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-4.04 per share while it has a forward price to earnings multiple of 2.4655 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Agios Pharm’s profitability.

Agios Pharm stock is trading at a EV to sales ratio of 107.3145 and a EV to EBITDA ratio of -2.7625. Its price to sales ratio in the trailing 12-months stood at 164.392.

Agios Pharm stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$1.24 billion

Total Liabilities

$62.63 million

Operating Cash Flow

$82.95 million

Capital Expenditure

$113000

Dividend Payout Ratio

0%

Agios Pharm ended 2023 with $1.24 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.24 billion while shareholder equity stood at $1.10 billion.

Agios Pharm ended 2023 with $0 in deferred long-term liabilities, $62.63 million in other current liabilities, 71000.00 in common stock, $-470561000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $139.26 million and cash and short-term investments were $783.12 million. The company’s total short-term debt was $13,663,000 while long-term debt stood at $0.

Agios Pharm’s total current assets stands at $832.77 million while long-term investments were $313.87 million and short-term investments were $643.86 million. Its net receivables were $2.21 million compared to accounts payable of $18.62 million and inventory worth $8.49 million.

In 2023, Agios Pharm's operating cash flow was $82.95 million while its capital expenditure stood at $113000.

Comparatively, Agios Pharm paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$22.55

52-Week High

$34.76

52-Week Low

$16.75

Analyst Target Price

$37.8

Agios Pharm stock is currently trading at $22.55 per share. It touched a 52-week high of $34.76 and a 52-week low of $34.76. Analysts tracking the stock have a 12-month average target price of $37.8.

Its 50-day moving average was $26.1 and 200-day moving average was $26.79 The short ratio stood at 10.99 indicating a short percent outstanding of 0%.

Around 135% of the company’s stock are held by insiders while 10776.4% are held by institutions.